Interest in rare diseases has expanded in recent years, as evidenced by politicians' and health authorities' agendas, yet ultra-rare diseases still receive far too little attention. Although no legal classification of an "ultra-rare" disease has been created, the National Institute for Health and Care Excellence has informally designated this subcategory for medications having indications for disorders with a prevalence of less than one in per 50 000 people. The approach by which ultra-rare disease research should be conducted, as well as the question of quality, are both critical considerations. Although less stringent criteria may be used for orphan pharmaceuticals than for drugs treating more prevalent diseases, this should not be used as an excuse to deny people with rare diseases the best available treatment. When a patient is diagnosed with a rare or ultra-rare condition, having the correct physician and treatment plan is just as vital as having a support system.
Title : The foundation for rare disease and its role in the european rare disease research landscape
Daniel Scherman, Foundation for Rare Diseases, France
Title : The effect of Eupalinolide B on amyotrophic lateral sclerosis: A case report
Wang Huaixiu, Shanxi Provincial Hospital, China
Title : Progress related in genetic research on kawasaki disease
Jiao Fuyong, Shaanxi Provincial People’s Hospital, China
Title : Covid-19 seems to be Initiated by the heparan-sulfate dysregulation by coronavirus: The use of low-molecular- weight heparin (LMWH) can prevent and treat covid-19 when it Is used in early stages, as a heparan-sulfate-regulating medicine
Fereshteh Sedaghat, Sedaghat Memory Clinic, Iran (Islamic Republic of)
Title : Lumevoq gene therapy in leber hereditary optic neuropathy
Magali Taiel, GenSight Biologics, France
Title : Drug recommendation system using a collaborative filtering in machine learning
J. Somasekar, Jain University, India